MedTrace Logo

177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer

NCT03647657 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2022-02-10

No results posted yet for this study

Summary

The purpose of this study is to determine the use of 177Lu-PP-F11N for imaging and therapy of patients with advanced medullary thyroid carcinoma (MTC). 177Lu-PP-F11N is a gastrin analogon, binding to cholecystokinin-2 receptors. This receptors show an overexpression on more than 90 % of medullary thyroid carcinomas.

Conditions

  • Thyroid Cancer, Medullary

Interventions

DRUG

177Lu-PP-F11N

Intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and without co-medication with Sacuitril (100 mg Entresto) in each patient

DRUG

Sacuitril

Medication with Sacuitril (100 mg Entresto) additional to the injection of 177Lu-PP-F11N

Sponsors & Collaborators

  • University Hospital, Zürich

    collaborator OTHER

  • University Hospital Freiburg

    collaborator OTHER

  • Krebsforschung Schweiz, Bern, Switzerland

    collaborator OTHER

  • Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland

    collaborator OTHER

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Christof Rottenburger, Dr. med. · University Hospital Basel, Clinic for radiology and nuclear medicine

  • Damian Wild, PhD Dr · University Hospital Basel, Clinic for radiology and nuclear medicine

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-13
Primary Completion
2021-12-14
Completion
2021-12-14

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03647657 on ClinicalTrials.gov